Dallas is focusing on new and advanced treatments, like those that use cells or genes. They are also looking at how biology ...

Tissue expansion, originally developed for super-resolution imaging, has become a foundation for expansion omics (ExO), a ...

TSRA-196 is a potential one-time treatment to precisely correct the genetic mutation underlying AATD, with Investigational New Drug filing ...

Q32 Bio Inc. ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and other autoimmune and inflammatory diseases, today announced ...

Guided by the "Healthy China 2030" strategy, governments, institutions, and enterprises are jointly investing in the health industry, continuously raising residents' health awareness. With the ...

The SBIO ETF has staged a remarkable comeback, outperforming despite a challenging macro backdrop and small-cap weakness.

Molecular glues are revolutionizing cancer therapy by targeting undruggable proteins for degradation, enhancing precision ...

Robust growth is propelled by rising demand for regulatory writing, clinical documentation, and drug development. Medical ...

Reflects accelerated progression of Phase 2 CALMA trial and pre-clinical small molecule assets. Driven primarily by the $1.1 million non-cash profit from the strategic divestiture of the Vancouver ...

Internet of Behaviors (IoB) market projection signals robust CAGR driven by exponential data proliferation, AI-driven ...

Global South groups oppose ITPGRFA expansion as seed sovereignty and digital biopiracy fears grow; rising farmer protests ...